Ribonucleic Acid (RNA) Interference Technology Market Report 2026
Global Outlook – By Product Type (Reagents, Kits, Services), By Delivery Method (Liposome Based, Viral Vector Based, Nanoparticle Based, Other Delivery Methods), By Technology (Gene Editing Technology, Clustered Regularly Interspaced Short Palindromic Repeats Cas9 Technology), By Application (Gene Silencing, Transcriptional Gene Regulation, Therapeutic Development, Agricultural Biotechnology), By End User (Pharmaceutical Companies, Academic Research Institutions, Biotechnology Companies, Contract Research Organizations) – Market Size, Trends, Strategies, and Forecast to 2030
Ribonucleic Acid (RNA) Interference Technology Market Report 2026 Market Overview
• Ribonucleic Acid (RNA) Interference Technology Market Report 2026 market size has reached to $4.67 billion in 2025 • Expected to grow to $8.57 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Rising Oncology Therapeutics Demand Fueling The Growth Of The Market Due To Increasing Global Cancer Incidence • Market Trend: Advancements In Conditionally Activated RNA Interference (RNAi) Technology Enhance Precision Gene Silencing And Targeted Therapeutic Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Ribonucleic Acid (RNA) Interference Technology Market?
A ribonucleic acid (RNA) interference technology is a biological process used to regulate gene expression by silencing specific messenger RNA (mRNA) molecules within cells. It utilizes small RNA molecules to block the production of targeted proteins involved in cellular functions and disease pathways. A ribonucleic acid (RNA) interference technology is widely applied in molecular biology, drug discovery for studying gene function and controlling abnormal gene activity. The main product types of ribonucleic acid (RNA) interference technology include reagents, kits, and services. Reagents refer to specialized substances used to facilitate RNA interference processes for gene expression regulation and functional studies. These products use delivery methods such as liposome based, viral vector based, nanoparticle based, and other delivery methods and technologies including gene editing technology and clustered regularly interspaced short palindromic repeats Cas9 technology. The various applications involved are gene silencing, transcriptional gene regulation, therapeutic development, and agricultural biotechnology, and they are used by several end users such as pharmaceutical companies, academic research institutions, biotechnology companies, and contract research organizations.
What Is The Ribonucleic Acid (RNA) Interference Technology Market Size and Share 2026?
The ribonucleic acid (RNA) interference technology market size has grown rapidly in recent years. It will grow from $4.67 billion in 2025 to $5.29 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to rising use of gene knockdown techniques in research laboratories, expansion of genomic sequencing capabilities, increasing funding for molecular biology research, early adoption of sirna-based experimental therapies, growth in academic-industry collaboration for gene function studies.What Is The Ribonucleic Acid (RNA) Interference Technology Market Growth Forecast?
The ribonucleic acid (RNA) interference technology market size is expected to see rapid growth in the next few years. It will grow to $8.57 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing clinical approvals of rna-based therapeutics, growing demand for precision medicine and targeted gene silencing, advancements in delivery technologies improving in vivo efficiency, expansion of biotech pipelines focused on genetic diseases, rising investment in RNA interference drug discovery platforms. Major trends in the forecast period include expansion of RNA-based therapeutics targeting rare genetic disorders and oncology applications, increasing focus on off-target effect reduction and improved gene silencing accuracy in RNai systems, advancements in RNA stability enhancement and chemical modification of siRNA molecules, growing adoption of lipid-based and non-viral delivery systems for efficient intracellular RNA transport, rising integration of RNai platforms in functional genomics and high-throughput target validation pipelines.
Global Ribonucleic Acid (RNA) Interference Technology Market Segmentation
1) By Product Type: Reagents, Kits, Services 2) By Delivery Method: Liposome Based, Viral Vector Based, Nanoparticle Based, Other Delivery Methods 3) By Technology: Gene Editing Technology, Clustered Regularly Interspaced Short Palindromic Repeats Cas9 Technology 4) By Application: Gene Silencing, Transcriptional Gene Regulation, Therapeutic Development, Agricultural Biotechnology 5) By End User: Pharmaceutical Companies, Academic Research Institutions, Biotechnology Companies, Contract Research Organizations Subsegments: 1) By Reagents: Small Interfering Ribonucleic Acid Reagents, Micro Ribonucleic Acid Reagents, Short Hairpin Ribonucleic Acid Reagents, Transfection Reagents, Gene Silencing Reagents, Ribonucleic Acid Delivery Reagents, Ribonuclease Protection Reagents, Control Reagents 2) By Kits: Small Interfering Ribonucleic Acid Isolation Kits, Micro Ribonucleic Acid Extraction Kits, Gene Silencing Assay Kits, Transfection Kits, Complementary Deoxyribonucleic Acid Synthesis Kits, Ribonucleic Acid Purification Kits, Quantitative Polymerase Chain Reaction Kits, Ribonucleic Acid Interference Screening Kits 3) By Services: Ribonucleic Acid Interference Screening Services, Gene Silencing Validation Services, Assay Development Services, Transfection Optimization Services, Custom Small Interfering Ribonucleic Acid Design Services, Bioinformatics Analysis Services, Target Identification Services, Drug Discovery ServicesWhat Is The Driver Of The Ribonucleic Acid (RNA) Interference Technology Market?
The increasing oncology therapeutics demand is expected to propel the growth of the ribonucleic acid (RNA) interference technology market going forward. Oncology therapeutics refers to medications and treatment approaches used to prevent, manage, and treat cancer by targeting cancer cells, controlling tumor growth, or reducing the spread of the disease. Oncology therapeutics are increasing due to the rising global incidence of cancer, which is driving demand for advanced treatment options such as targeted therapies, immunotherapies, and personalized medicines to improve patient outcomes. RNA Interference (RNAi) technology supports oncology therapeutics by enabling the targeted silencing of cancer-related genes involved in tumor growth, metastasis, and drug resistance. For instance, in May 2025, according to the National Cancer Institute, a US-based government agency, approximately 2,041,910 new cancer cases are projected to be diagnosed in the United States, with an estimated 618,120 deaths attributed to the disease. Therefore, the increasing oncology therapeutics demand is driving the growth of the ribonucleic acid (RNA) interference technology industry.Key Players In The Global Ribonucleic Acid (RNA) Interference Technology Market
Major companies operating in the ribonucleic acid (RNA) interference technology market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Silence Therapeutics plc, Revvity Inc., QIAGEN N.V., Takara Bio Inc., Arrowhead Pharmaceuticals Inc., Bioneer Corporation, Alnylam Pharmaceuticals Inc., Novo Nordisk A/S, Integrated DNA Technologies, GeneCopoeia Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Ribonucleic Acid (RNA) Interference Technology Market Trends and Insights
Major companies operating in the ribonucleic acid (RNA) interference technology market are focusing on developing advanced platforms, such as conditionally activated small interfering RNA (siRNA) molecules, to improve cell-specific targeting, enhance therapeutic efficacy, and expand the application of RNA-based medicines. Conditionally activated siRNA (CASi) refers to a novel RNAi approach that activates gene-silencing activity only in selected cells, enabling more precise and controlled therapeutic interventions. For instance, in March 2023, Switch Therapeutics, a US-based biotechnology company, launched its proprietary CASi platform following a $52 million Series A financing round. The platform integrates nucleic acid nanotechnology with RNA interference science to enable cell-selective gene knockdown, efficient self-delivery, prolonged therapeutic activity, and targeted activation of siRNA molecules in specific cell types. The company intends to utilize the funding to advance its lead central nervous system (CNS) disease program and accelerate the development of next-generation RNAi therapeutics.What Are Latest Mergers And Acquisitions In The Ribonucleic Acid (RNA) Interference Technology Market?
In June 2024, GSK plc, a UK-based pharmaceutical company, acquired Elsie Biotechnologies, Inc. and its oligonucleotide discovery platform for $50 million. With this acquisition, GSK aimed to strengthen its oligonucleotide and RNA interference technology capabilities by enhancing its platform for gene expression modulation and accelerating the development of advanced RNA-based therapeutics and precision medicine applications. Elsie Biotechnologies is a US-based biotechnology company that is involved in the broader ribonucleic acid (RNA) interference (RNAi) technology ecosystem through its work in oligonucleotide therapeutics.
Regional Outlook
North America was the largest region in the ribonucleic acid (RNA) interference technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Ribonucleic Acid (RNA) Interference Technology Market?
The ribonucleic acid (RNA) interference technology market consists of revenues earned by entities by providing services such as cell line engineering, functional genomics research, target gene validation, drug discovery screening, pathway analysis, biomarker identification, crop trait improvement, antiviral research development. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA) interference technology market also includes sales of small interfering ribonucleic acid (siRNA), micro ribonucleic acid (miRNA) products, transfection reagents, ribonucleic acid (RNA) delivery systems, and gene expression analysis tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Ribonucleic Acid (RNA) Interference Technology Market Report 2026?
The ribonucleic acid (rna) interference technology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) interference technology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Ribonucleic Acid (RNA) Interference Technology Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $5.29 billion |
| Revenue Forecast In 2030 | $8.57 billion |
| Growth Rate | CAGR of 12.8% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Product Type, Delivery Method, Technology, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Silence Therapeutics plc, Revvity Inc., QIAGEN N.V., Takara Bio Inc., Arrowhead Pharmaceuticals Inc., Bioneer Corporation, Alnylam Pharmaceuticals Inc., Novo Nordisk A/S, Integrated DNA Technologies, GeneCopoeia Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |